Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation.
D000280:Administration, Inhalation; D056668:Cathepsin L / Q000378:metabolism*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004847:Epithelial Cells / Q000166:cytology; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D008168:Lung / Q000166:cytology / Q000378:metabolism; D009000:Monocytes / Q000166:cytology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000008:administration & dosage* / Q000627:therapeutic use
D008081:Liposomes; D011994:Recombinant Proteins; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D056668:Cathepsin L